This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Best Practices in IBD: Treatment Approaches

Best Practices in IBD: Treatment Approaches


Expert Perspective

Time to Complete

45 minutes


December 12, 2017


December 12, 2018
Add to Queue

Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider

This educational activity is provided by the American Gastroenterological Association.

Commercial Supporter

Supported by an educational grant from Takeda Pharmaceuticals


Produced by Haymarket Medical Education (HME)

Program Description

Contemporary thinking about inflammatory bowel disease (IBD) treatment strategies is more proactive than reactive, based on the principle that inflammation should be controlled as early in possible in the course of the disease. Immediate treatment goals are the control of symptoms, induction of remission, and improvement of quality of life (QoL), while long-term goals include maintenance of a corticosteroid-free clinical remission, mucosal healing, endoscopic remission, prevention or cure of complications, restoration and maintenance of proper nutrition, and improvement of QoL. Rather than following a standardized course of treatment, it is now understood that induction and maintenance regimens should be tailored to the severity of the individual patient’s disease activity. In this activity, Dr. Russell Cohen outlines the principles of IBD management in the context of a case scenario of a patient with ulcerative colitis.

Intended Audience

Gastroenterologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians who manage patients with IBD

Educational Objectives

At the conclusion of this activity, participants should be better able to:

  • Describe biologic and nonbiologic treatments for inflammatory bowel disease (IBD), including their advantages and disadvantages
  • Apply quality measures and quality outcome indicators to assess quality of care and responses to treatment

Conflict Of Interest Disclosure Policy

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.


Russell D. Cohen, MD
Professor of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
University of Chicago Medicine
Chicago, IL

Dr. Cohen is on the speakers’ bureaus for AbbVie Inc. and Takeda Pharmaceuticals and is a consultant, advisor, and/or on the advisory board of AbbVie Inc., Celgene, Eli Lilly, Hospira, Janssen, Pfizer Inc., Sandoz Biopharmaceuticals, Takeda Pharmaceuticals, and UCB Pharma. He has been a principal investigator for clinical trials for AstraZeneca, Celgene, Gilead Sciences, MedImmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer Inc., Receptos, RedHill Biopharma, Sanofi-Aventis, and UCB Pharma. Additionally, Dr. Cohen discloses that his spouse is on the board of directors for the following companies: Protein Sciences, Tokai Pharmaceuticals, Vital Therapies, Inc., and CytRx Corporation.

Accredited Provider and Publishing Staff Disclosures

No other individuals involved with planning and delivering the content disclosed any relevant financial relationships.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The AGA Institute designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. AGA Institute, Haymarket Medical Education, and Takeda Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AGA Institute, Haymarket Medical Education, or Takeda Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


AGA Institute does not provide any warranty as to the accuracy or reliability of information presented either verbally or in writing by presenters. No responsibility is assumed by AGA Institute for any injury and/or damage to persons or property resulting from any use of such information.

If you have any questions relating to the accreditation of this activity, please contact the AGA education department at or 301-654-2055.


To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue